巨星醫療控股(02393.HK)2022年收益同比下跌約12.9%至42.94億元
格隆匯3月31日丨巨星醫療控股(02393.HK)公吿,截至2022年12月31日止年度的全年業績,收益同比下跌約12.9%至約人民幣42.94億元。2022年的年內虧損約為人民幣10.2億元,而2021年則錄得溢利約人民幣1270萬元。2022年歸屬於母公司擁有人的虧損約為人民幣9.9億元,而2021年則錄得溢利約人民幣330萬元。每股虧損為人民幣42.6分,而2021年則錄得每股盈利人民幣0.1分。董事會不建議就2022年度派發末期股息(2021年:無)。
集團的使命為擴大並鞏固市場份額,晉身中國最大體外診斷產品經銷商及服務供應商列,以自有品牌製造體外診斷試劑,並通過採納既定的業務模式及策略以及審慎風險及資本管理框架,維持長期可持續盈利能力及資產增長。
為使本集團得以落實業務模式及提升盈利能力,董事會創造出尊重及有利交流研發意念的文化以及財務及經營程序,管理層將於本集團上下全面落實及鞏固其企業文化。董事會領導本集團宗旨、價值及策略方針的制訂工作,並營造高瞻遠足及重視競爭力的文化。
有關文化已經形成,並於本集團的營運慣例、職場政策及實務以及持份者關係中貫徹反映。董事會一直以來監察文化的措施與工具包括與團隊溝通、挽留與培訓僱員、恪守財務彙報規定、實施有效而方便的舉報系統、遵守法律及監管規定(包括遵守操守守則及集團政策)以及確保員工安全、福利及支援等。
為達至可持續發展及提高股東長遠價值,於2022年度,集團致力推廣體外診斷產品,並計劃就生物化學系列產品取得79項註冊證書,其中42項已經取得,而餘下各項亦已完成註冊評估,預期快將取得。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.